DLX-2323 / Arrivo - LARVOL DELTA

Rethinking immunogenicity: an integrated approach reveals the PK/PD impact of pre-existing and drug-sustaining ADA. (PubMed, Bioanalysis) - "Pre-existing ADA magnitude correlated with a drug-sustaining impact on PK and PD, with lower clearance (CL/F) and volume of distribution (Vd/F) of DLX-2323 relative to increasing ADA signal. Based on the immunogenicity risk assessment, the use of ADA-sensitive free PK and PD assays to measure in vivo ADA effects on drug exposure and PD activity provided clinically meaningful information that standalone neutralizing antibody assays could not."

Journal • PK/PD data • IL1B